Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
Authors:
- 11 August 2007
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (12) , 1943-1952
Abstract
In patients with lymphoma, we investigated the impact of contrast-enhanced CT on PET attenuation correction in lesions and normal tissues, particularly when PET/CT was performed after chemotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of MDCT Radiation Dose: A Phantom StudyAmerican Journal of Roentgenology, 2006
- Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical EvaluationAmerican Journal of Roentgenology, 2006
- FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphomaBlood, 2006
- The contribution of PET/CT to improved patient managementBritish Journal of Radiology, 2006
- FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphomaAnnals of Oncology, 2005
- [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcomeBlood, 2005
- 16-detector multislice CT: dosimetry estimation by TLD measurement compared with Monte Carlo simulationBritish Journal of Radiology, 2004
- Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Whole-Body Positron Emission Tomography—CT: Optimized CT Using Oral and IV Contrast MaterialsAmerican Journal of Roentgenology, 2002
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999